Monoclonal Antibody to Charcot Leyden Crystal Protein (CLC)
| Code | Size | Price |
|---|
| MAC387Hu21-20ul | 20ul | £89.00 |
Quantity:
| MAC387Hu21-100ul | 100ul | £166.00 |
Quantity:
| MAC387Hu21-200ul | 200ul | £224.00 |
Quantity:
| MAC387Hu21-1ml | 1ml | £515.00 |
Quantity:
Prices exclude any Taxes / VAT
Overview
Host Type: Mouse
Antibody Clonality: Monoclonal
Regulatory Status: RUO
Target Species: Human
Applications:
- Enzyme-Linked Immunosorbent Assay (ELISA)
- Immunocytochemistry (ICC)
- Immunohistochemistry- Frozen Section (IHC-F)
- Immunohistochemistry- Paraffin Embedded (IHC-P)
- Western Blot (WB)
Documents
Further Information
Alternative Names:
LGALS10; LPPL; Eosinophil Lysophospholipase; Lysolecithin Acylhydrolase; Galectin 10
Buffer Formulation:
0.01M PBS, pH7.4, containing 0.01% Proclin-300, 50% glycerol.
Item Name:
Charcot Leyden Crystal Protein
Potency (Clone Number):
C2
Source:
Monoclonal antibody preparation
Usage:
Western blotting: 0.5-5ug/ml<br/>Immunocytochemistry in formalin fixed cells: 5-30ug/ml<br/>Immunohistochemistry in formalin fixed frozen section: 5-30ug/ml<br/>Immunohistochemistry in paraffin section: 5-30ug/ml<br/>Enzyme-linked Immunosorbent Assay: 0.05-2ug/ml<br/>Optimal working dilutions must be determined by end user.
Related Products
| Product Name | Product Code | Supplier | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Immunogen | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Recombinant Charcot Leyden Crystal Protein (CLC) | RPC387Hu01 | Cloud-Clone Corp. | Summary Details | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||